Mining the mechanisms of an HIV vaccine

作者：Plotkin Stanley A; Robinson Harriet L; Davenport Miles P

来源：Nature Medicine, 2012, 18(7): 1020-1021.

DOI：10.1038/nm.2858

Despite the existence of antiretroviral drugs that can combat HIV, it is thought that the development of an effective vaccine will be required to control the spread of this deadly virus. In 2009, the results from a phase 3 trial (RV144) of a vaccine consisting of a combination of a canarypox vector expressing HIV-1 immunogens and a recombinant HIV-1 envelope protein offered some hope, as the vaccine showed modest efficacy in preventing HIV-1 infection (31.2%) in a Thai population. Barton Haynes et al.(1) have now performed a case-control analysis to investigate the immune correlates of protection provided by this vaccine. They found that IgG antibody binding of the variable regions 1 and 2 (V1 and V2) of the HIV-1 envelope (Env) glycoprotein 120 inversely correlated with the rate of HIV-1 infection, and plasma IgA antibody binding to Env directly correlated with the rate of infection. We asked three experts to comment on how these results affect our understanding of immune-mediated protection from HIV and how they might be used to design future vaccine strategies against this virus.
[GRAPHICS]
.

• 出版日期2012-7